COMMUNIQUÉS West-GlobeNewswire

Wounded Warriors Family Support Provides Veterans with Program Toward Financial Competency, Independence
20/09/2024
OMAHA, Neb., Sept. 20, 2024 (GLOBE NEWSWIRE) -- According to a 2021 Military Family Support Programming Survey, 80.7% of respondents indicated that their finances caused them some stress over the past 12 months. The [...]
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
20/09/2024
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment [...]
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
20/09/2024
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its [...]
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
20/09/2024
CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
20/09/2024
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the [...]
ChemoMetec makes offer to buy Ovizio Imaging Systems SA
20/09/2024
ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
20/09/2024
Please see enclosed pdf. Attachment 20092024_trading_in_shares_LRA
Range Impact Announces Application to Uplist to the OTCQB Venture Market
20/09/2024
CLEVELAND, OHIO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to improving the health and wellness of people and the planet through a [...]
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
19/09/2024
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
ADR Ratio Change
19/09/2024
September 19, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a [...]
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
19/09/2024
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization [...]
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
19/09/2024
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for [...]
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
19/09/2024
Trésorerie et équivalents de trésorerie s’éle vant à 61,6 m illio ns d’euros au 30 juin 2024 n’incluant pas le paiement d’étape de 48,7 millions d’euros facturé en juin 2024 (reçu en août 2024) lors de la première vente [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
19/09/2024
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/09/2024
SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19/09/2024
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart [...]
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19/09/2024
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira [...]
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
19/09/2024
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics [...]
Rejuveron Life Sciences AG prend le nom de Centenara Labs AG et fait le point sur les dernières données cliniques
19/09/2024
Les actionnaires approuvent le changement de dénomination sociale sous la marque Centenara Labs AG (« Centenara ») Le changement de marque positionne l’entreprise pour des initiatives stratégiques destinées à soutenir [...]

Pages